Skip to main content
. 2020 Jul 3;9(1):1785608. doi: 10.1080/2162402X.2020.1785608

Figure 4.

Figure 4.

Tumor cell killing by RevCAR system in mice.

(a–d) As indicated, seven different groups each consisting of five NMRI-Foxn1nu/nu mice were analyzed in parallel in one experiment. One control group was transplanted with luciferase-expressing LNCaP tumor cells alone (identical in a–d). Additional control mice were injected with LNCaP tumor cells together with either RevCAR-E5B9-28/3z (a, c) or RevCAR-E7B6-28/3z (b, d) T cells without RevTM. In the treatment groups, RevCAR-E5B9-28/3z (a, c) or RevCAR-E7B6-28/3z (b, d) T cells were co-injected with luciferase-expressing LNCaP tumor cells with indicated RevTMs. (a–b) After administration of D-Luciferin, optical imaging was performed at different time points. (c–d) Measured luminescence was evaluated using the Bruker MI and Multispectral Software (n = 5, mean ± SEM, Two-Way ANOVA with Tukey’s multiple comparisons test. Significance versus tumor cells with RevCAR T cells w/o RevTM is shown.).